|
The TB treatment and prophylaxis market has experienced limited growth
and activity over the last 40 years, as companies have perceived TB as
primarily a "poor disease". However, the market now looks to hold
greater potential, with rising incidence in the US, and improved
diagnostics creating a renewed demand for both vaccination and
therapeutics.
Overview of TB pathology and epidemiology
Review of current TB diagnostic technologies and areas of unmet
need in the diagnostics market
Assessment of current TB treatment, highlighting areas of unmet
need and potential market opportunity
Analysis of the prophylaxis market providing strategic insight
into clinical trial design and strategies for market penetration
There are three key areas within the TB market with high levels of
unmet need, namely diagnostics, therapeutics, and prophylaxis.
TB vaccines with higher efficacy and longevity will help to persuade
governments in the developed world to reconsider including TB
prophylaxis in immunization schedules.
Improvements in the rapidity and accuracy of diagnostic technologies
will drive patient potential and market growth. The development of
second line treatment options for resistant infection will increase
the value of the TB treatment market.
Identify the areas of the TB market which offer the highest
potential for new market entrants
Understand the changing competitive dynamics in the TB market
Identify the key epidemiological trends for TB in the major
markets
|
